Amelioration of flulike symptoms at the onset of interferon β-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction

Annals of Neurology

Volumn 44, Issue 4, 1998, Pages 682-685

  Martinez Caceres E M ^a   Rio J ^a   Barrau, M ^a   Duran I ^a   Borras C ^a   Tintore M ^a   Montalban, X ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERFERON BETA SERINE; INTERLEUKIN 10; INTERLEUKIN 6; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CASE REPORT; DRUG EFFICACY; FLU LIKE SYNDROME; HUMAN; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACETAMINOPHEN; ADMINISTRATION, ORAL; ADULT; ANALGESICS, NON-NARCOTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEVER; GLUCOCORTICOIDS; HUMANS; INFLUENZA, HUMAN; INTERFERON-BETA; INTERLEUKIN-6; MIDDLE AGED; MULTIPLE SCLEROSIS; PREDNISONE;

EID: 0031784843     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410440415     Document Type: Article

References (19)

1. The IFN-β Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-661
2. Jacobs L, Cookfair D, Rudick RA, et al. Intramuscular interferon β-1a for disease progression in relapsing multiple sclerosis: The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-294
3. IFN-β Multiple Sclerosis Study Group, University of British Columbia MS/MRI Analysis Group. Interferon beta-1b in the treatment of MS: final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285
4. Neilley LK, Goodin DS, Goodkin DE, et al. Side effects profile of interferon beta-1b in multiple sclerosis: results of a open label trial. Neurology 1996;46:552-554
5. Río J, Nos C, Marzo ME, et al. Low oral steroid use reduces flu-like symptoms at the onset of IFN β-1b therapy in relapsing-remitting multiple sclerosis. Neurology 1998;50: 1910-1912
6. Roth J, Hopkins SJ, Hoadley ME, et al. Fever and production of cytokines in response to repeated injections of muramyl dipeptide in guinea pigs. Pflugers Arch 1997;434:525-533
7. Blay JY, Rossi JF, Wijdenes J, et al. Role of IL-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma. Int J Cancer 1997;72:424-430
8. Engervall P, Granstrom M, Andersson B, et al. Endotoxemia in febrile patients with hematological malignancies. Relationship of type of bacteriemia, clinical findings and serum cytokine patterns. Infection 1997;25:2-7
9. 1b treatment decreases tumor necrosis factor-α and increases intetleukin-6 production in multiple sclerosis. Neurology 1996; 46:1633-1638
10. Dayal AS, Jensen MA, Lledó A, et al. Interferon-gamma secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology 1995;45:2173-2177
11. Arnason BGW. Interferon beta in multiple sclerosis. Clin Immunol Immunopathol 1996;81:1-11
12. Hall GL, Compston A, Scolding NJ. Beta-interferon and multiple sclerosis. Trends Neurosci 1997;20:63-67
13. Noronha A, Toscas A, Jensen MA. Interferon β decreases T cell activation and interferon γ production in multiple sclerosis. J Neuroimmunol 1993;46:145-154
14. Rudick RA, Carpenter CS, Cookfair DL, et al. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant intetferon beta. Neurology 1993;43:2080-2087
15. Rep MHG, Hintzen RQ, Polman CH, et al. Recombinant interferon-β blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol 1996; 67:111-118
16. Rudick RA, Ransohoff RM, Peppler R, et al. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol 1996;40:618-627
17. Porrini AM, Gambi D, Reder AT. Interferon effects on interleukin-10 secretion: mononuclear cell response to interleukin-10 is normal in multiple sclerosis patients. J Neuroimmunol 1995;61:27-34
18. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain 1997;120:865-916
19. Abu Khabar KS, Amstrong JA, Ho M. Type I interferons (IFN-alpha and -beta) suppress cytotoxin tumor necrosis factor-alpha and lymphotoxin production by mitogen-stimulated human peripheral blood mononuclear cells. J Leukoc Biol 1992;52:165-172